Abbonarsi

Azalomycin F5a, a polyhydroxy macrolide binding to the polar head of phospholipid and targeting to lipoteichoic acid to kill methicillin-resistant Staphylococcus aureus - 09/12/18

Doi : 10.1016/j.biopha.2018.11.067 
Ganjun Yuan a, ⁎ , Li Xu a, Xuejie Xu a, Peibo Li b, Qiwang Zhong a, Hailin Xia a, Yamei Hu a, Pingyi Li a, Xiaoyuan Song a, Junfang Li a, Qianru Liu a
a College of Bioscience and Bioengineering, Jiangxi Agricultural University, Nanchang 330045, China 
b College of Life Sciences, Sun Yat-Sen University, 135 Xingan Road, Guangzhou 510275, China 

⁎ Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

pagine 11
Iconografia 10
Video 0
Altro 0

Graphical abstract

This research confirmed that azalomycin F 5a can increase the membrane permeability of MRSA cell, and which had likely achieved by the synergy of its lactone ring binding to the polar head of phospholipid and its guanidyl side chain targeting to lipoteichoic acid (LTA). This would subsequently cause the release of cellular substance, and eventually lead to the autolysis of MRSA cells. Nevertheless, it is unknown how azalomycin F 5a interacts with MRSA cellular LTA, such as influencing the physiological function of LTA, inhibiting LTA synthase and polymerase, and/or accelerating the release of LTA?




Il testo completo di questo articolo è disponibile in PDF.

Highlights

•
Azalomycin F 5a can increase cell-membrane permeability to kill Staphylococcus aureus .
•
Azalomycin F 5a disrupts the cell membrane by interacting with phospholipid.
•
The lactone ring of azalomycin F 5a can stably bind to the polar head of phospholipid.
•
Azalomycin F 5a -induced lysis of MRSA can be inhibited by cellular lipoteichoic acid.
•
The guanidyl chain of azalomycin F 5a likely targets to lipoteichoic acid of S. aureus .

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Azalomycin F 5a was a polyhydroxy macrolide produced by streptomycete strains. Our preliminary researches indicated that it could kill methicillin-resistant Staphylococcus aureus (MRSA) likely by increasing the permeability of cell membrane, and that cell-membrane phospholipids were likely important targets. To confirm this, membrane permeability assay was performed and visualized by fluorescence staining, and then the detailed interactions between azalomycin F 5a and model membranes prepared with 1,2-dihexadecanoyl- sn -glycero-3-phospho-(1'- rac -glycerol) (DPPG) were determined using attenuated total reflectance fourier transform infrared spectroscopy and 31 P nuclear magnetic resonance techniques. The results indicated that there were strong interactions between azalomycin F 5a and model membranes, especially between azalomycin F 5a and the polar head of phospholipid. For further evidence and details, the molecular dynamics (MD) simulation of the interactions between azalomycin F 5a and DPPG or lysyl-DPPG were performed using Amber16 software package. A strong interaction between the lactone ring of azalomycin F 5a and the polar head of DPPG or lysyl-DPPG had been clearly observed. Moreover, a larger distribution probability out of phospholipid bilayer had been discovered for the guanidyl side chain of azalomycin F 5a , especially when probable anion molecules anchoring on the cytoplasmic membrane occurred. Therefore, lipoteichoic acid (LTA), a vital component of gram-positive bacterial envelope, was investigated for its probable interactions with azalomycin F 5a using broth microdilution method. The results showed that azalomycin F 5a -induced MRSA lysis could be prevented by LTA. This deduced that there were some interactions between azalomycin F 5a , more likely its guanidyl side chain, and LTA. Thereby, azalomycin F 5a increasing the cell-membrane permeability of MRSA had likely achieved by the synergy of its lactone ring binding to the polar head of phospholipid and its guanidyl side chain targeting to LTA, and which had eventually led to the autolysis of MRSA cells.

Il testo completo di questo articolo è disponibile in PDF.

Chemical compounds studied in this article :  Azalomycin F 5a (CID: 73425500) , DPPG (CID: 65144), Lysyl-DPPG (CID: 122706358)

Keywords : Azalomycin F, Lipoteichoic acid, Phospholipid, MRSA, Macrolide, Phosphatidylglycerol


Mappa


© 2018  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 109

P. 1940-1950 - gennaio 2019 Ritorno al numero
Articolo precedente Articolo precedente
  • Dual-function of triptriolide in podocytes injury: inhibiting of apoptosis and restoring of survival
  • Yi-qi Yang, Jian Liang, Xiao-dong Han, Rui-min Tian, Xu-sheng Liu, Wei Mao, Hong-tao Xu, Bo Liu, Peng Xu
| Articolo seguente Articolo seguente
  • Neferine inhibits growth and migration of gastrointestinal stromal tumor cell line GIST-T1 by up-regulation of miR-449a
  • Fangxi Xue, Zhaoxia Liu, Jian Xu, Xiaoguang Xu, Xingtian Chen, Feng Tian

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.